Fraunhofer-Institut für Zelltherapie und Immunologie IZIAntikörpertechnologien
- Köppen J, Kleinschmidt M, Morawski M, Rahfeld J-U, Wermann M, Cynis H, Hegenbart U, Daniel C, Roßner S, Schilling S, Schulze A. Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis. Amyloid. 2024, 31 (3): 184-194. doi: 10.1080/13506129.2024.2358121. Epub 2024 May 27.
- Schrempel S, Kottwitz AK, Piechotta A, Gnoth K, Büschgens L, Hartlage-Rübsamen M, Morawski M, Schenk M, Kleinschmidt M, Serrano GE, Beach TG, Rostagno A, Ghiso J, Heneka MT, Walter J, Wirths O, Schilling S, Roßner S. Identification of isoAsp7-Aβ as a major Aβ variant in Alzheimer’s disease, dementia with Lewy bodies and vascular dementia. Acta Neuropathol. 2024, 148 (1): 78. doi: 10.1007/s00401-024-02824-9
- Gnoth K, Piechotta A, Kleinschmidt M, Konrath S, Schenk M, Taudte N, Ramsbeck D, Rieckmann V, Geissler S, Eichentopf R, Barendrecht S, Hartlage-Rübsamen M, Demuth H-U, Roßner S, Cynis H, Rahfeld J-U, Schilling S. Targeting isoaspartate-modified Aβ rescues behavioral deficits in transgenic mice with Alzheimer's disease-like pathology. Alzheimers Res Ther. 2020 Nov 14;12(1):149. doi: 10.1186/s13195-020-00719-x
- Hettmann T, Gillies SD, Kleinschmidt M, Piechotta A, Makioka K, Lemere CA, Schilling S, Rahfeld J-U, Lues I. Development of the clinical candidate PBD-C06, a humanized pGlu3-Aβ-specific antibody against Alzheimer's disease with reduced complement activation. Sci Rep. 2020 Feb 24;10(1):3294. doi: 10.1038/s41598-020-60319-5
- Sebastian Monasor L, Müller SA, Colombo AV, Tanrioever G, König J, Roth S, Liesz A, Berghofer A, Piechotta A, Prestel M, Saito T, Saido TC, Herms J, Willem M, Haass C, Lichtenthaler SF, Tahirovic S. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. Elife. 2020 Jun 8;9:e54083. doi: 10.7554/eLife.54083
- Hartlage-Rübsamen M, Bluhm A, Piechotta A, Linnert M, Rahfeld J-U, Demuth H-U, Lues I, Kuhn P-H, Lichtenthaler SF, Roßner S, Höfling C. Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation. Molecules. 2018 Apr 17;23(4):924. doi: 10.3390/molecules23040924
- Piechotta A, Parthier C, Kleinschmidt M, Gnoth K, Pillot T, Lues I, Demuth H-U, Schilling S, Rahfeld J-U, Stubbs MT. Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy. J Biol Chem. 2017 Jul 28;292(30):12713-12724. doi: 10.1074/jbc.M117.777839. Epub 2017 Jun 16.